HDL Functionality Video Interview

2 AMA PRA Category 1 Credit(s)™
Launch Date:
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

No primary audience was provided.

Relevant Terms:

No primary audience was provided.

H. Bryan Brewer, Jr., MD, FNLA

H. Bryan Brewer, Jr., MD, FNLA
Director, Washington Cardiovascular Associates
Senior Research Consultant
Lipoprotein and Atherosclerosis Research
MedStar Research Institute
Washington Hospital Center
Washington, DC

H. Bryan Brewer, Jr., MD, is director of the Washington Cardiovascular Associates and senior research consultant of lipoprotein and atherosclerosis research in the Cardiovascular Research Institute, MedStar Research Institute, Washington Hospital Center in Washington, DC. From 1976 to 2005, he held the position of chief of the Molecular Disease Branch of the National Heart, Lung, and Blood Institute (NHLBI) of the NIH in Bethesda, Maryland.

Dr. Brewer earned his Bachelor of Science from Johns Hopkins University in Baltimore, Maryland, and his Doctorate of Medicine from Stanford University School of Medicine in Stanford, California. He completed his internship and residency training in internal medicine at Massachusetts General Hospital in Boston, Massachusetts, after which he joined the NHLBI of the NIH in Bethesda, Maryland.

Dr. Brewer's research led to the elucidation of the first published sequences for the human plasma apolipoproteins, the initial determination of the metabolism of the plasma apolipoproteins in normal and hyperlipidemic individuals, as well as the identification of multiple gene defects leading to the genetic dyslipoproteinemias. In addition, he pioneered the use of transgenic mice and rabbits as well as recombinant adenovirus vectors to identify genes that modulate lipoprotein metabolism and the development of atherosclerosis. Most recently, his research has focused on acute HDL therapy employing HDL infusions to decrease atherosclerosis in patients with acute coronary syndrome.

Dr. Brewer has been the recipient of the JD Lane Investigator Award from the Public Health Service; the Heinrich Wieland Prize from the Federal Republic of Germany; and the Public Health Service Commendation, Meritorious Service, and Distinguished Service Medals from the NIH. He has served as a member of the board of the National Cholesterol Education Program, which established treatment guidelines for patients with hyperlipidemia in the United States. He has published more than 400 original reports and 70 reviews and book chapters on the subjects of genetic dyslipoproteinemias, lipoprotein metabolism, and atherosclerosis.

Robert S. Rosenson, MD, FACC, FAHA, FACP, FNLA

Robert S. Rosenson, MD, FACC, FAHA, FACP, FNLA
Director, Cardiometabolic Disorders
Mount Sinai Heart
Professor of Medicine
Mount Sinai School of Medicine
New York, New York

Robert S. Rosenson, MD, FACC, FAHA, FACP, is the director of cardiometabolic disorders at Mount Sinai Heart Institute and professor of medicine at Mount Sinai School of Medicine in New York City. Previously, he was the division chief of endocrinology, diabetes, and metabolism at SUNY Downstate Medical Center in Brooklyn, New York. Prior to his time in New York, Dr. Rosenson was the director of lipoprotein disorders and clinical atherosclerosis research and professor of medicine at the University of Michigan School of Medicine in Ann Arbor as well as an attending physician in the Department of Medicine of the University of Michigan Health System.
Dr. Rosenson earned his medical degree from Tulane University in New Orleans, Louisiana. He then served his residency in medicine at Brigham and Women's Hospital in Boston, Massachusetts. He later completed a fellowship in cardiology at the University of Chicago.
Dr. Rosenson has been involved in numerous grant-supported research investigations studying the effects of lipid-lowering therapy; hypoglycemic therapy; and antihypertensive agents in inflammation, thrombogenesis, and rheology. He has served as principal investigator on a number of National Institutes of Health (NIH)-funded research studies, pharmaceutical-sponsored drug trials, and multicenter studies. He has been an invited speaker at more than 150 national and international association meetings, grand rounds, and symposia. He has authored more than 600 journal articles, book chapters, abstracts, and electronic publications.
Dr. Rosenson is a diplomate of the American Board of Internal Medicine, with a subspecialty in cardiovascular disease; the National Board of Medical Examiners; and the National Lipid Association. He currently serves on a number of committees for professional societies and as a member of the Program Committee and Expert Document Committee for the American College of Cardiology. He is a fellow of the American Heart Association Council on Epidemiology and Prevention, and he is a fellow of the American Heart Association Council on Arteriosclerosis, Thrombosis, and Vascular Biology. He has been the recipient of a number of awards and honors, including the Ground-Breaking Doctors Award from Chicago magazine.

Benjamin J. Ansell, MD, FACC, FACP, FNLA

Benjamin J. Ansell, MD, FACC, FACP, FNLA
Professor of Medicine, Division of Cardiology
Co-Director, Cholesterol, Hypertension and
Atherosclerosis Management Program (CHAMP)
UCLA School of Medicine
Los Angeles, California

Benjamin J. Ansell, MD, FACC, FACP, FNLA, received a dual undergraduate degree in biology and music from Cornell University, Ithaca, New York, and his Doctor of Medicine from the University of California Los Angeles (UCLA) School of Medicine, where he subsequently performed an internship and residency in internal medicine. Dr. Ansell currently serves as professor of medicine at the UCLA School of Medicine in the Divisions of General Internal Medicine and Cardiology. He also serves as co-director of the UCLA Cholesterol, Hypertension, & Atherosclerosis Management Program (CHAMP) and director of the UCLA Cardiovascular Discovery Fund.
Dr. Ansell is a fellow of both the American College of Physicians and the American College of Cardiology, a board member of the National Lipid Association, a member of the American Heart Association Council on Arteriosclerosis, Thrombosis, and Vascular Biology, and a diplomate of both the American Board of Internal Medicine and the American Board of Clinical Lipidology. He is also past president of the executive board of the UCLA Department of Medicine.
Chosen by US News and Town & Country magazines as one of the "Best Physicians in America," Dr. Ansell is also a prominent researcher of HDL and its relationship to vascular inflammation and heart disease. He has been principal investigator of the hs-CRP and HDL Effects of Statins Trial (CHEST), the Statins/HDL Increased Function Trial (SHIFT), and the Statin Anti-Rheumatic Activity (SARA) Trial. In addition, he authored or co-authored more than 50 scientific papers and book chapters. He has also been featured by The New York Times, CNN, ABC World News Tonight, 20/20, MSNBC, Dateline NBC, and National Public Radio.
Dr. Ansell serves on the board of directors for Ashford Hospitality Trust (NYSE:AHT). He also is a member of the board of overseers for the Los Angeles Philharmonic Association. Previously from New York state and Colorado, Dr. Ansell has lived in Los Angeles for the last twenty-four years. He is married with three children.

Philip Barter, MD, PhD

Philip Barter, MD, PhD
Director, The Heart Research Institute
Professor of Medicine, University of Sydney
Sydney, Australia

Director, The Heart Research Institute
Professor of Medicine, University of Sydney
Sydney, Australia
Philip J. Barter, MD, PhD, FRACP, is director of The Heart Research Institute, in Sydney, Australia, and also a professor of medicine at the University of Sydney. He graduated in medicine from the University of Adelaide in Adelaide, South Australia, and gained his PhD from the Australian National University in Canberra. He is a fellow of the Royal Australasian College of Physicians. Currently president elect of the International Atherosclerosis Society, he also is a member of the International Task Force for the Prevention of Coronary Heart Disease and is an executive member of the International Chair on Cardiometabolic Risk. He is the 2011 recipient of the Anitschkow Award of the European Atherosclerosis Society.
Professor Barter has held positions previously in research institutes and universities in Australia and the United States. His basic research interests are plasma lipids and lipoproteins, specifically high-density lipoproteins, the factors that regulate them, and the mechanism by which they protect against cardiovascular disease. His clinical research involves participation in clinical trials of lipid-lowering agents.
Professor Barter was a member of the steering committees of the FIELD study and the TNT Study and was co-chair of the steering committee of the DEFINE study. He also was chairman of the steering committee of the ILLUMINATE trial. He currently is a member of the steering committees of the DalOutcomes trial and the REVEAL HPS-3 TIMI-55 trial, 2 large-scale clinical outcome trials assessing the efficacy of new cholesteryl ester transfer protein (CETP) inhibitors. He has published more than 300 peer-reviewed research papers on plasma lipids and lipoproteins, their metabolism, regulation, function, and relationship to atherosclerosis. He also has written handbooks on HDL and CETP inhibitors. Recognizing that atherosclerosis has become a major global epidemic, he is committed to the development of atherosclerosis research and education programs in countries beyond North America and Western Europe, including South and Southeast Asia, South and Central America, the Middle East, and Africa.

M. John Chapman, BSc, PhD, DSc, FACC

M. John Chapman, BSc, PhD, DSc, FACC
Director, Dyslipidemia, Inflammation and
Atherosclerosis Research Unit of the National
Institute of Health and Medical Research (INSERM)
Pitié and Salpêtrière University Hospital
President, European Atherosclerosis Society
Paris, France

M. John Chapman, BSc, PhD, DSc, FACC, is director of the Dyslipidemia, Inflammation and Atherosclerosis Research Unit of the National Institute for Health and Medical Research (INSERM Unit 939) at the Pitié-Salpétrière Hospital in Paris, France, which is affiliated with the Medical Faculty of the Pierre and Marie Curie University in Paris. Professor Chapman is the president of the European Atherosclerosis Society, chairman of the Gordon Research Conference on Atherosclerosis in Newport, Rhode Island (2011), and a fellow of the European Society of Cardiology.

Professor Chapman received his BSc at the University of Aberdeen, Scotland, and his PhD at Middlesex Hospital Medical School, University of London. After postdoctoral training at the Cardiovascular Research Institute, University of California Medical Center, San Francisco, he became an established research investigator at INSERM in 1978.

Professor Chapman has authored more than 400 peer-reviewed publications and book chapters. In recognition of his contributions to the field of "Plasma Lipoproteins: Structure, Metabolism and Role in Atherothrombosis", he was awarded the Doctor of Science degree by the University of London in 2002.
Professor Chapman's main research interests include the structure, metabolism and biological activities of atherogenic apo B-containing particle subspecies (VLDL, LDL and Lp(a)), the relationship of HDL particle heterogeneity to atheroprotective activity in normolipidemia and atherogenic dyslipidemia, the role of CETP in the regulation of intravascular lipoprotein metabolism, the pharmacological modulation of lipoprotein metabolism and its involvement in atherogenic dyslipidemias, and metabolic disease and the role of monocyte-macrophages and foam cells in the inflammatory destabilization and thrombogenicity of atherosclerotic plaques.

Jay W. Heinecke, MD

Jay W. Heinecke, MD
Professor, Department of Medicine
Division of Metabolism, Endocrinology and Nutrition
Karasinski Chair in Metabolic Research
University of Washington School of Medicine
Seattle, Washington

Jay Heinecke, MD, earned his medical degree from Washington University in St. Louis, Missouri, in 1981 and then relocated to the University of Washington (UW) for a residency in internal medicine. He was also a postdoctoral fellow in the Division of Metabolism, Endocrinology and Nutrition and then a senior fellow in the UW Department of Biochemistry from 1987 until 1990. He was a faculty member at Washington University in St. Louis from 1991 until 2002, when he became professor of medicine and professor of molecular biology and pharmacology there. In 2002, he returned to the UW to take his current position. He also directs the Mass Spectrometry Resource in the Department of Medicine and is an attending physician at UW Medical Center and a member of the Molecular and Cellular Biology Graduate Program. He holds the Karasinski Chair in Metabolic Research.
Dr. Heinecke has received numerous awards, including the American Heart Association's Jeffrey M. Hoeg Arteriosclerosis, Thrombosis and Vascular Wall Biology Award in 2001 and an Excellence in Mentoring Award from the Washington University Graduate Student Senate in 2002. He is a member of several editorial boards, including the Journal of Clinical Investigation, the Journal of Lipid Research, and the Journal of Biological Chemistry.

Dr. Heinecke's research focuses on understanding the role of macrophages and HDL in the pathogenesis of atherosclerosis, diabetes, and obesity. A major effort is directed towards using proteomics and mice with genetically engineered proteins to understand macrophage activation. His current studies include: proteomics approaches to understand the cell biology of macrophages and dendritic cells—immune cells derived from circulating monocytes—that are implicated in the pathogenesis of inflammatory diseases; the use of animals with genetically engineered deficiencies in phagocyte oxidant generation and MMPs to understand the role of oxidants and proteases in the pathogenesis of cardiovascular disease; and human and animal studies exploring the links between the HDL proteome, insulin resistance, and susceptibility to cardiovascular disease.

Nancy R. Webb, PhD

Nancy R. Webb, PhD
Professor of Medicine
University of Kentucky
Lexington, Kentucky

Nancy R. Webb, PhD, is professor of medicine in the Department of Internal Medicine, Division of Endocrinology at the University of Kentucky Medical Center, where she has been an integral contributor to their Department of Internal Medicine for 17 years. She earned her PhD in Microbiology and Immunology from the University of Kentucky in Lexington, and previously earned a BA degree in Biology from the University of Virginia in Charlottesville.
Dr. Webb has received numerous honors and awards over the years, including the annual University of Kentucky Wethington Research Award from 2004-2011. She was also a finalist in 2004 for the Irvine H. Page Young Investigator Research Award from the American Heart Association, Council on Arteriosclerosis, Thrombosis and Vascular Biology. She has been invited to speak at many national and international conferences on topics including, "Recent insights into (unexpected) functions of secretory phospholipase A2's"; "Role of Group X sPLA2 in adipose tissue"; "Group V sPLA2 in atherosclerosis: An update"; and "Secretory phospholipase A2's: Old and new functions".
Dr. Webb has authored or co-authored more than 60 articles. She is actively involved in the American Heart Association, currently serving as Chair of the Great Rivers Affiliate Research Committee and as a member of the board of directors for the Great Rivers Affiliate. She is also a member of the leadership committee for the AHA Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB), and serves as chair of the ATVB Women's Leadership Committee. She is an editorial board member for the Journal of Lipid Research and Arteriosclerosis, Thrombosis, and Vascular Biology. She is involved in numerous studies and has received NIH grant funding support for her active research.
1. Discuss the role of HDL in macrophage-derived cholesterol efflux and the primary anti-atherosclerotic function of HDL particles
2. Describe the multiple proteins associated with HDL particles and their putative role in mediating the antioxidant, anti-inflammatory, and immunological functions associated with HDL particles
3. Discuss the effects of the acute phase response on HDL particles and the implications for its functionality and potential relevance in acute coronary syndromes
4. List the available and potential laboratory and clinical measures of HDL functionality